Qualified upstream sourcing. ISO 9001 certified Korean processing. Accredited verification. KORECOA documentation. Built for institutional procurement review.
Crude peptide intermediate sourced through AVODAGEN Limited from GMP-compliant manufacturers with FDA registration and EU regulatory standing. Suppliers evaluated against establishment registration, regulatory filings, inspection history including Form 483 record, and ICH-compatible standards before commercial purchase.
Final purification, lyophilization, and quality release at the ISO 9001 certified Korean partner facility, coordinated through our Korean operating partner NovaBridge Co., Ltd. with PIC/S GMP-certified Korean peptide CDMO processing. Real value-add chemistry supports substantial transformation. Not transhipment or paperwork.
Each batch tested at accredited Korean laboratory partner, independent of supplier and processor. Release panel: HPLC purity and identity, mass spectrometry, water content, endotoxin, residual solvents, heavy metals.
Exported from Korea through NovaBridge Co., Ltd. with complete documentation: supplier qualification, batch processing records, release test results, origin documentation, KORECOA portal access.
Standard supply is research-grade material processed at the ISO 9001 certified Korean partner facility under the four-stage operating model above. Pharmaceutical-grade engagements are available through custom development for qualified institutional partners by request, with scope and processing path confirmed during qualification.
KORUS Free Trade Agreement provides preferential tariff treatment where substantial transformation rules are met. AVODAGEN's operating model is structured around real Korean chemistry, meaningful value-add, and documented processing — designed to support Korean origin qualification under applicable trade frameworks.
Korean-origin API designed to support preferential tariff treatment under KORUS framework. Model is structured to support qualification, not assume it.
Origin determinations consider whether processing materially changes the article through real chemistry. Model is built around substantial transformation principles.
Korean origin claims supported with batch-level documentation: certificate of origin, processing records, analytical method validation, release records. Trade counsel engagement planned.
ISO/IEC 17025 is the international standard for laboratory competence: validated methods, traceable measurement, third-party audit. AVODAGEN structures batch release through accredited Korean laboratory partnerships — independent of supplier and processor.
Verification framework built around independent Korean accredited laboratory partnerships. Third-party accountability separate from supplier or operator, designed for institutional procurement review.
Each batch is designed to undergo the analytical testing intended for pharmaceutical batch release, performed independently of the supplier and the processor. Results documented under accredited laboratory standards with chain of custody and method validation records.
KORECOA accompanies each batch processed through the AVODAGEN operating model. The platform consolidates supplier qualification, processing records, accredited test results, and origin documentation into a single verifiable package with batch-level traceability and an append-only audit trail.
Supplier qualification, regulatory standing, inspection records.
ISO 9001 Korean partner batch records, in-process controls, yield analysis.
Full accredited release panel results from Korean laboratory partner.
Certificate of origin, substantial transformation records, trade documentation.
Operational discipline matters as much as operational capability. The exclusions are explicit and constant.
Sources only from qualified and documented suppliers with verifiable regulatory standing.
Research material and API supplier only. Does not compound, fill, or distribute finished dose forms.
Verified business registration required. No direct consumer sales. Research use only.
Does not list, quote, or supply molecules under active clinical trial protection or third-party patent protection where AVODAGEN does not hold appropriate rights.
Qualified partners receive the full operating documentation package on completion of qualification.
Request Qualified Partner Access →